With Staphefekt, the first targeted therapy against S. aureus is available for long-term daily maintenance therapy, aimed at decreasing the burden of skin colonisation and preventing progression to inflammation and infection.
Staphefekt – intervening early in the Colonisation Infection Continuum with endolysins
Share this article
Find out more
Prevalence and odds of Staphylococcus aureus carriage in atopic dermatitis: a systematic review and meta-analysis
Staphylococcus aureus and Staphylococcus epidermidis strain diversity underlying pediatric atopic dermatitis